Patents by Inventor Ernesto Perea
Ernesto Perea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082392Abstract: Use of the peptide identified as SEQ ID NO: 1 for manufacturing a medicine which induces antitumor and antiviral immunity by immunogenic cell death. The invention also provides a method for treating cancer or viral infections by using therapeutically effective amounts of a drug that comprises the synthetic peptide of the invention. This method induces antitumor and antiviral immunity by immunogenic cell death. Also, the invention comprises the pharmaceutical combination of the peptide identified as SEQ ID NO: 1 and cancer immunotherapy approaches, which achieve stronger immunotherapeutic management to combat this disease.Type: ApplicationFiled: November 23, 2021Publication date: March 14, 2024Inventors: Daylen AGUILAR NORIEGA, Silvio Ernesto PEREA RODRÍGUEZ, Yasser PERERA NEGRÍN, Dania, Marcia VÁZQUEZ BLOMQUIST, Gilda, Enrique LEMOS PÉREZ, Idania, Caridad BALADRÓN CASTRILLO, Pablo, Arsenio DÍAZ REYES
-
Patent number: 9278118Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: October 20, 2014Date of Patent: March 8, 2016Assignees: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 9226946Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: September 19, 2014Date of Patent: January 5, 2016Assignees: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Publication number: 20150111832Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: ApplicationFiled: October 20, 2014Publication date: April 23, 2015Inventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lárazo Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Publication number: 20150030700Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: ApplicationFiled: September 19, 2014Publication date: January 29, 2015Inventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 8871725Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: February 28, 2007Date of Patent: October 28, 2014Assignee: Centro de Ingeniería Genética y BiotecnologíaInventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodriguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Patent number: 8748411Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.Type: GrantFiled: May 5, 2006Date of Patent: June 10, 2014Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gómez
-
Patent number: 8007776Abstract: Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide. Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.Type: GrantFiled: October 8, 2003Date of Patent: August 30, 2011Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Alicia Santos Savio, Ricardo Silva Rodriguez, Yanelis Morera Diaz, Armando Alexei Rodriquez Alfonso, Jose Rafael Martinez Castillo, Haydee Geronimo Perez, Alejandro Moro Soria, Silvio Ernesto Perea Rodriguez
-
Patent number: 7947287Abstract: This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.Type: GrantFiled: April 8, 2008Date of Patent: May 24, 2011Assignee: Centro de Ingenieria Genetica y BiotecnolgiaInventors: Silvio Ernesto Perea Rodriquez, Osvaldo Reyes Acosta, Nelson Francisco Santiago Vispo, Yaquelin Puchades Izaguirre, Ricardo Silva Rodriguez, Alejandro Moro Soria, Alicia Santos Savio, Luis Javier Gonzalez Lopez, Belkis Gonzalez Barrios
-
Patent number: 7736638Abstract: Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15R?) and TNF?-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R? expression is associated to the disease progression.Type: GrantFiled: September 16, 2005Date of Patent: June 15, 2010Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Alicia Santos Savio, Ania Cabrales Rico, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Celia Aurora Arrieta Aguero, Silvio Ernesto Perea Rodriguez
-
Publication number: 20090215730Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.Type: ApplicationFiled: May 5, 2006Publication date: August 27, 2009Inventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gomez
-
Publication number: 20090136511Abstract: Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor ? subunit (IL15R?) and TNF?-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R? expression is associated to the disease progression.Type: ApplicationFiled: September 16, 2005Publication date: May 28, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Alicia Santos Savio, Ania Cabrales Rico, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Celia Aurora Arrieta Aguero, Silvio Ernesto Perea Rodriguez
-
Publication number: 20090130228Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: ApplicationFiled: February 28, 2007Publication date: May 21, 2009Inventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodriguez Ulloa, Jeovanis Gil Valdes, Yassel Ramos Gomez, Lila Rosa Castellanos Serra, Lazaro Hiram Betancourt Nunez, Aniel Sanchez Puente, Jorge Fernandez de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier Gonzalez Lopez, Vladimir Besada Perez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Publication number: 20090005294Abstract: This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.Type: ApplicationFiled: April 8, 2008Publication date: January 1, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodriquez, Osvaldo Reyes Acosta, Nelson Francisco Santiago Vispo, Yaquelin Puchades Izaguirre, Ricardo Silva Rodriguez, Alejandro Moro Soria, Alicia Santos Savio, Luis Javier Gonzalez Lopez, Belkis Gonzalez Barrios
-
Patent number: 7374767Abstract: This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.Type: GrantFiled: December 4, 2002Date of Patent: May 20, 2008Assignee: Centro de Ingenieria Genetica y BiotechologiaInventors: Silvio Ernesto Perea Rodriguez, Osvaldo Reyes Acosta, Nelson Francisco Santiago Vispo, Yaquelin Puchades Izaguirre, Ricardo Silva Rodriguez, Alejandro Moro Soria, Alicia Santos Savio, Luis Javier González López, Belkis González Barrios
-
Patent number: 6287936Abstract: The method is for forming porous silicon in a silicon substrate, in particular for improving the quality factor of an inductive circuit produced on a silicon semiconductor wafer which also incorporates integrated transistors. The rear face of the wafer, already incorporating the transistors and the inductive circuit on its front face, is placed in contact with an acid electrolyte containing hydrofluoric acid and at least one other acid. An anodic oxidation of the silicon of the wafer at the rear face is carried out so as to convert this silicon into porous silicon over a predetermined height from the rear face which is in contact with the electrolyte.Type: GrantFiled: May 4, 1999Date of Patent: September 11, 2001Assignees: STMicroelectronics S.A., France TelecomInventors: Ernesto Perea, Guillermo Bomchil, Aomar Halimaoui
-
Patent number: 5367183Abstract: Disclosed is a system with at least two complementary transistors, having n and p channels but comprising a heterostructure of junctions between III-V group materials. In order to balance the threshold voltages in the two channels, namely the n (2DEG) and p (2DHG) channels, at least two p and n delta doped layers are included in two layers of the heterostructure, at levels included between the channels (2DEG, 2DHG) and the gate electrodes. The n delta doped layer is then removed by localized etching right above the p channel transistor. Application to fast logic circuits.Type: GrantFiled: April 7, 1993Date of Patent: November 22, 1994Assignee: Thomson-CSF Semiconducteurs SpecifiquesInventors: Ernesto Perea, Daniel Delagebeaudeuf
-
Patent number: 5045727Abstract: This interface constitutes an adaptation of the output signals of a first circuit, made of silicon for example, to the limit values of the input signals in a second digital circuit, made of GaAs for example. It includes a first stage (A) consisting of two parallel-mounted shifters, in which the input signal (E) and a reference (Ref) are shifted. A second stage (B), of the BFL type, compares these two values and a third stage (C) regenerates and amplifies the signals. A fourth stage (D) may give a complementary value. This interface is integrated into the chip of the second digital circuit which is made of GaAs.Type: GrantFiled: June 15, 1990Date of Patent: September 3, 1991Assignee: Thomson Composants MicroondesInventors: Jean-Yves Danckaert, Ernesto Perea
-
Patent number: 5043607Abstract: This interface constitutes a matching of the output signals of a first circuit, made of GaAs for example, with the limit values of the input signals of a second digital circuit, made of silicon for example. It has a current amplifier which receives the output signal of the GaAs circuit. The voltages at the high level are controlled by a diode in series with a transistor which is then on. At the low level, the transistor is off, and it is two diodes, in parallel with the transistor, that control the output voltage. This interface is integrated into the chip of the digital circuit, made of GaAs. Single figure.Type: GrantFiled: June 19, 1990Date of Patent: August 27, 1991Assignees: Thomson Composants Microondes, Thomson-CSFInventors: Jean-Yves Danckaert, Ernesto Perea
-
Patent number: 4721985Abstract: The invention relates to a variable capacitance element operating in the ultra-high frequency range. In order to integrate this element on to an integrated circuit chip, the element is designed so that the control voltage does not interfere with the ultra-high frequency signal and has neither filters nor shock chokes which are not integrable. The element according to the invention utilizes the junction capacitances variation of at least one diode, reverse-biased by a voltage across a resistor, the high frequency signal being at the diode anode. The element construction comprises an active zone in a semiinsulating substrate. Two metallizations partly cover the active zone and form therewith at least one diode. A projection to the active zone forms the resistor, to which is applied the control voltage. The diodes are p-n junctions of schottky diodes. The semiconductor material is Si or from the III-V group. Application to oscillators, filters, phase shifters, etc. in ultra-high frequency equipment.Type: GrantFiled: July 1, 1985Date of Patent: January 26, 1988Assignee: Thomson-CSFInventors: Dimitrios Pavlidis, Erhard Kohn, Ernesto Perea, John Magarshack